Benefits of a next comparative analyze have been documented by Flinn et al. This can be a stage III randomized Intergroup trial comparing FC program as opposed to FAMP alone in 278 patients obtaining their initial chemotherapy program for B-CLL. Dosages of FC program ended up the same as the primary